Table 4.
Course of Symptoms as assessed in 21 ovarian cancer patients with the ovarian cancer-specific module (OV-28) of the EORTC Quality of Life core questionnaire
| EORTC QLQ-OV28c | |||||||
|---|---|---|---|---|---|---|---|
| Baselinea | CT 3b | CT 6 | AC1b | AC2 |
constant term/ beta coefficient |
||
| Abdominal Symptoms (AS) | 41.9 (28.1) | 21.8 | 29.2 | 20.5 | 13.5 (21.7) |
36.8/-3.0 | t = -2.72; p = 0.009 |
| Peripheral Neuropathy (PN) | 32.8 (26.2) | 37.7 | 39.2 | 37.7 | 23.1 (26.1) | 35.3/-0.5 | t = -0.39; p = 0.697 |
| Other Chemotherapy-related Side Effects (CSE) | 30.2 (33.8) | 29.3 | 29.8 | 23.0 | 1.6 (2.7) |
42.4/-5.7 | t = -5.97; p < 0.001 |
| Hormonal/menopausal Symptoms (HS) | 34.1 (35.1) | 22.2 | 26.5 | 31.5 | 22.2 (31.2) | 30.2/-0.8 | t = -0.55; p = 0.587 |
| Body Image (BI) | 73.0 (33.1) | 74.5 | 84.3 | 75.0 | 77.8 (25.0) | 74.2/0.8 | t = 0.68; p = 0.502 |
| Attitudes towards Disease and Treatment (AT) |
26.1 (22.6) | 39.5 | 56.9 | 53.7 | 66.7 (24.6) | 27.1/5.4 | t = 5.30; p < 0.001 |
| Sexual Functioning (SF) | 47.9 (21.9) | 64.3 | 48.8 | 57.3 | 57.4 (12.8) | 48.9/1.0 | n = 8 |
a Baseline (CT1)
b CT chemotherapy cycle, AC aftercare
c Reference values (ovarian cancer patients, all stages) [54]: AS = 21.9 (22.1), PN = 17.1 (27.2), CSE = 19.5 (20.5), HS = 25.8 (30.3), BI = 22.2 (27.4), AT = 42.3 (30.6)